

MODULE 2.5

CLINICAL OVERVIEW

Latanoprost/Pharmathen

(eye drops solution containing 50 micrograms/ml (0.005%) latanoprost)

**Pharmacist, Doctor of Medicine,
Specialised in Clinical Pharmacology and Toxicology,
Ex-assistant Professor of Forensic Toxicology,
School of Medicine, University of Athens**

**Pharmacist
Senior Clinical & Biopharmaceutical Expert
Specialised in Clinical Toxicology
Pharmathen S.A, Athens, Greece**

Table of Contents

2.5.1. PRODUCT DEVELOPMENT RATIONALE	6
2.5.2. OVERVIEW OF BIOPHARMACEUTICS	7
2.5.2.1. COMPOSITIONS OF LATANORPOST/PHARMATHEN AND XALATAN	7
2.5.2.2. COMPARISON OF PHYSICOCHEMICAL PROPERTIES OF LATANOPROST/PHARMATHEN 0.005% AND XALATAN 0.005%	10
2.5.2.3. COMPARATIVE OCULAR PHARMACOKINETIC STUDY OF TEST FORMULATION (LATANOPROST+TIMOLOL) AND REFERENCE FORMULATION OF XALACOM IN MALE NEW ZEALAND WHITE RABBITS (VLL/0117/G/D003).....	11
2.5.2.4. CONCLUSION.....	12
2.5.3. OVERVIEW OF CLINICAL PHARMACOLOGY.....	13
2.5.3.1. OVERVIEW OF HUMAN PHARMACODYNAMICS.....	13
2.5.3.1.1. Mechanism of action.....	13
2.5.3.1.2. Effects on intraocular pressure.....	14
2.5.3.1.3. Effects on blood flow.....	16
2.5.3.1.3.1. <i>Studies in healthy individuals</i>	16
2.5.3.1.3.2. <i>Studies in glaucoma patients</i>	17
2.5.3.1.4. Pharmacodynamic drug interactions.....	18
2.5.3.2. OVERVIEW OF CLINICAL PHARMACOKINETICS.....	19
2.5.3.2.1. Ocular pharmacokinetics	19
2.5.3.2.2. Systemic pharmacokinetics after intravenous and topical administration on the eye .	19
2.5.3.2.3. Maximum plasma concentrations during chronic treatment.....	19
2.5.3.2.4. Metabolites in urine and feces	19
2.5.3.2.5. Pharmacokinetics in special populations	20
2.5.4. OVERVIEW OF EFFICACY.....	21
2.5.4.1. OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION	21
2.5.4.1.1. Efficacy of preservative-free latanoprost.....	21
2.5.4.1.2. Efficacy of BAK-preserved latanoprost.....	22
2.5.4.1.2.1. <i>Concentration and administration considerations</i>	22
2.5.4.1.2.1.1. <i>Concentration</i>	22
2.5.4.1.2.1.2. <i>Administration: Once versus twice daily</i>	23
2.5.4.1.2.1.3. <i>Administration: Morning versus night</i>	23
2.5.4.1.2.1.4. <i>Administration: Once every other day versus once daily</i>	24
2.5.4.1.2.1.5. <i>Meta-analysis</i>	24
2.5.4.1.2.2. <i>Monotherapy</i>	25
2.5.4.1.2.2.1. <i>Comparative studies</i>	25
2.5.4.1.3.1.2. <i>Latanoprost vs dorzolamide</i>	29

2.5.4.1.3.1.3. <i>Latanoprost vs brimonidine</i>	30
2.5.4.1.3.1.4. <i>Latanoprost vs other prostaglandin analogues</i>	32
2.5.4.1.3.1.4.1. <i>Latanoprost vs bimatoprost</i>	32
2.5.4.1.3.1.4.2. <i>Latanoprost vs travoprost</i>	34
2.5.4.1.3.1.4.3. <i>Latanoprost vs bimatoprost or travoprost</i>	36
2.5.4.1.3.1.4.4. <i>Latanoprost vs unoprostone alone or in combination</i>	36
2.5.4.1.3.1.4.5. <i>Latanoprost vs tafluprost</i>	38
2.5.4.1.3.1.5. <i>Latanoprost vs multiple anti-glaucoma agents</i>	39
2.5.4.1.3.1.5.1. <i>Latanoprost vs timolol or bimatoprost</i>	39
2.5.4.1.3.1.5.2. <i>Latanoprost vs timolol or travoprost</i>	39
2.5.4.1.3.1.5.3. <i>Latanoprost vs bimatoprost or travoprost or timolol</i>	40
2.5.4.1.3.1.5.4. <i>Latanoprost vs AR-13324</i>	40
2.5.4.1.2.1.6. <i>Latanoprost vs combinations of antiglaucoma drugs</i>	41
2.5.4.1.2.1.6.1. <i>Latanoprost vs timolol/dorzolamide</i>	41
2.5.4.1.2.1.6.2. <i>Latanoprost vs timolol/pilocarpine</i>	44
2.5.4.1.2.1.6.3. <i>Latanoprost vs brimonidine/timolol</i>	45
2.5.4.1.2.1.6.4. <i>Latanoprost vs bimatoprost/timolol combination</i>	46
2.5.4.1.2.1.7. <i>Latanoprost vs other agents</i>	46
2.5.4.1.2.3. <i>Real-life non-comparative studies</i>	46
2.5.4.1.2.4. <i>Systematic reviews and meta-analyses</i>	48
2.5.4.1.2.4.1. <i>Antiglaucoma medicines</i>	48
2.5.4.1.2.4.2. <i>Prostaglandin analogues</i>	49
2.5.4.1.2.4.3. <i>Selective laser trabeculoplasty vs other treatment modalities for glaucoma</i>	51
2.5.4.1.2.5. <i>Adjunctive therapy</i>	52
2.5.4.1.2.5.1. <i>Latanoprost vs other antiglaucoma agents as adjunctive therapy</i>	52
2.5.4.1.2.5.2. <i>Added to beta-blockers</i>	53
2.5.4.1.2.5.3. <i>Added to other prostaglandin analogues</i>	54
2.5.4.1.2.5.4. <i>Added to dorzolamide</i>	54
2.5.4.1.2.5.5. <i>Added to acetazolamide</i>	54
2.5.4.1.2.5.6. <i>Added to physostigmine</i>	55
2.5.4.1.2.5.7. <i>Added to dipivefrin</i>	55
2.5.4.1.2.5.8. <i>Added to bunazosin</i>	55
2.5.4.1.2.5.9. <i>Added to taprenepag isopropyl</i>	55
2.5.4.1.2.5.10. <i>Added to ripasudil</i>	56
2.5.4.1.2.5.11. <i>Added to nepafenac</i>	56
2.5.4.1.2.5.12. <i>Added to various antiglaucoma agents</i>	56
2.5.4.1.2.5.13. <i>Added to dorzolamide-timolol fixed combination</i>	57
2.5.4.1.2.5.14. <i>Added to brinzolamide vs bimatoprost monotherapy, after latanoprost monotherapy</i>	57

2.5.4.1.2.5.15. <i>Real-life studies</i>	57
2.5.4.1.2.6. <i>Long-term treatment</i>	58
2.5.4.1.2.7. <i>Special topics of efficacy</i>	59
2.5.4.1.2.7.1. <i>Switching from other IOP lowering agents</i>	59
2.5.4.1.2.7.2. <i>Effects on intraocular pressure fluctuation</i>	60
2.5.4.1.2.7.3. <i>Effects on intraocular pressure in the supine position</i>	61
2.5.4.1.2.7.4. <i>Reduction of the frequency of visual field deterioration</i>	61
2.5.4.1.2.7.5. <i>Effects on quality of life</i>	62
2.5.4.1.2.7.6. <i>Patient persistence</i>	62
2.5.4.1.2.7.7. <i>Effects of ethnics</i>	62
2.5.4.1.2.7.8. <i>Effects of genotype</i>	63
2.5.4.1.2.7.9. <i>Treatment discontinuation studies</i>	65
2.5.4.2. PAEDIATRIC GLAUCOMA	66
2.5.4.2.1. Primary congenital glaucoma	66
2.5.4.2.2. Sturge-Weber syndrome	67
2.5.4.2.3. Various glaucoma diagnoses.....	67
2.5.4.2.4. Reviews.....	68
2.5.4.2.5. Long-term treatment	68
2.5.4.3. INDICATIONS UNDER INVESTIGATION	69
2.5.5. OVERVIEW OF SAFETY	70
2.5.5.1. OVERALL SAFETY/TOLERABILITY	70
2.5.5.1.1. Safety safety/tolerability profile of preservative-free latanoprost	70
2.5.5.1.2. Safety safety/tolerability profile of BAK-preserved latanoprost	70
2.5.5.2. SIDE/ADVERSE EFFECTS	71
2.5.5.3. SPECIAL TOPICS OF SAFETY	74
2.5.5.3.1. Ocular effects	74
2.5.5.3.1.1. <i>Conjunctival hyperaemia</i>	75
2.5.5.3.1.2. <i>Effects on iris colour and morphology</i>	78
2.5.5.3.1.3. <i>Hypertrichosis and hyperpigmentation of the eyelashes</i>	80
2.5.5.3.1.4. <i>Periocular pigmentation</i>	82
2.5.5.3.1.5. <i>Corneal punctate staining</i>	82
2.5.5.3.1.6. <i>Upper eyelid sulcus deepening</i>	82
2.5.5.3.1.7. <i>Cystoid macular oedema and uveitis</i>	84
2.5.5.3.1.8. <i>Herpes simplex keratitis reactivation</i>	86
2.5.5.3.1.9. <i>Effects on ocular surface</i>	86
2.5.5.3.1.10. <i>Cytotoxic effects</i>	89
2.5.5.3.1.11. <i>Ocular and/or cutaneous melanoma</i>	90
2.5.5.3.1.12. <i>Various periocular changes</i>	90

2.5.5.3.1.13. <i>Effects on astrocytes from the lamina cribrosa</i>	90
2.5.5.3.2. Systemic adverse effects	91
2.5.5.3.2.1. <i>Respiratory and cardiovascular effects</i>	91
2.5.5.3.2.2. <i>Headaches</i>	92
2.5.5.4. SAFETY IN SPECIAL POPULATIONS	92
2.5.5.5. PREGNANCY AND LACTATION	93
2.5.5.6. OVERDOSAGE.....	93
2.5.6. BENEFITS AND RISKS CONCLUSIONS	94
2.5.7. LIST OF LITERATURE REFERENCES	103

LIST OF ABBREVIATIONS

AE(s): adverse event(s)

BAK: benzalkonium chloride

BIM: bimatoprost

BP: blood pressure

CAI(s): carbonic anhydrase inhibitor(s)

CCT: central corneal thickness

COAG: chronic open-angle glaucoma

DOR: dorzolamide

DTFC: DOR/TIM fixed combination

IOP: intraocular pressure

LAT: latanoprost

NTG: normal tension glaucoma

OAG: open-angle glaucoma

ONH: optic nerve head

OH: ocular hypertension

OPP: ocular perfusion pressure

PF: Preservative-free

PG: prostaglandin

PGA(s): prostaglandin analogue(s)

POAG: primary open-angle glaucoma

SWS: Sturge-Weber syndrome

TIM: timolol

TRAV: travoprost

WMD: weighted mean difference

2.5.1. PRODUCT DEVELOPMENT RATIONALE

2.5.2. OVERVIEW OF BIOPHARMACEUTICS

2.5.3. OVERVIEW OF CLINICAL PHARMACOLOGY

2.5.4. OVERVIEW OF EFFICACY

2.5.5. OVERVIEW OF SAFETY

2.5.5.3.2. Systemic adverse effects

2.5.5.3.2.1. Respiratory and cardiovascular effects

2.5.7. LIST OF LITERATURE REFERENCES

(Articles in other than English language are included as abstracts,

Very recent articles that are not yet available in our country are included as abstracts)

Agange N, Mosaed S (2010): Prostaglandin-induced cystoid macular edema following routine cataract extraction; *J Ophthalmol*, 2010, 690707.

Aihara M, Oshima H, Araie M (2013): Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study; *Acta Ophthalmol*, 91, e7-e14.

Akman A, Cetinkaya A, Akova YA et al (2005): Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination; *Eye*, 19, 145-151.

Alaei M, Najmi AK, Kausar H et al (2015): A prospective research study of anti-glaucoma drugs prescribing, utilization pattern and adverse drug reaction recording in a university hospital; *Drug Res*, 65, 164-168.

Albert DM, Gangnon RE, Zimbric ML et al (2004): A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients; *Arch Ophthalmol*, 122, 1680-1685.

Albert DM, Gangnon RE, Grossniklaus HE et al (2008): A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides; *Arch Ophthalmol*, 126, 626-31.

Alimgil ML, Benian O (2002): Choroidal effusion and shallowing of the anterior chamber after adjunctive therapy with latanoprost in a trabeculectomized patient with angle closure glaucoma; *Int Ophthalmol*, 24, 129-131.

Alm A (2014): Latanoprost in the treatment of glaucoma; *Clin Ophthalmol*, 8, 1967-1985.

Alm A, Nilsson SF (2009): Uveoscleral outflow--a review; *Exp Eye Res*, 88, 760-768.

Alm A, Villumsen J (1991): PhXA34, a new potent ocular hypotensive drug: A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers; *Arch Ophthalmol*, 109, 1564-1568.

Alm A, Widengard I (2000): Latanoprost: experience of 2-year treatment in Scandinavia; *Acta Ophthalmol Scand*, 78, 71-76.

Alm A, Villumsen J, Tornquist P et al (1993): Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure: a one-month study; *Ophthalmology*, 100, 1312-1317.

Alm A, Stjernschantz J, Scandinavian Latanoprost Study Group (1995a): Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group; *Ophthalmology*, 102, 1743-1752.

Alm A, Widengard I, Kjellgren D et al (1995b): Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol; *Br J Ophthalmol*, 79, 12-16.

Alm A, Camras CB, Watson PG (1997): Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States; *Surv Ophthalmol*, 41(Suppl.2), S105-S110.

Alm A, Schoenfelder J, McDermott J (2004): A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma; *Arch Ophthalmol*, 122, 957-965.

Altieri M, Ferrari E (2011): Do prostaglandin analogs affect eyelid position and motility?; *J Ocul Pharmacol Ther*, 27, 511-517.

Altuna JC, Greenfield DS, Wand M et al (1999): Latanoprost in glaucoma associated with Sturge-Weber syndrome: benefits and side-effects; *J Glaucoma*, 8, 199-203.

Alvarado JA, Iguchi R, Martinez J et al (2010): Similar effects of selective laser trabeculoplasty and prostaglandin analogs on the permeability of cultured Schlemm canal cells; *Am J Ophthalmol*, 150, 254-264.

Amano S, Nakai Y, Ko A et al (2008): A case of keratoconus progression associated with the use of topical latanoprost; *Jpn J Ophthalmol*, 52, 334-336.

Anbar TS, El-Ammawi TS, Abdel-Rahman AT et al (2015): The effect of latanoprost on vitiligo: a preliminary comparative study; *Int J Dermatol*, 54, 587-593.

Ang A, Reddy MA, Shepstone L et al (2004): Long term effect of latanoprost on intraocular pressure in normal tension glaucoma; *Br J Ophthalmol*, 88, 630-634.

Anthony TL, Lindsey JD, Weinreb RN (2002): Latanoprost's effects on TIMP-1 and TIMP-2 expression in human ciliary muscle cells; *Invest Ophthalmol Vis Sci*, 43, 3705-3711.

Aptel F, Cucherat M, Denis P (2008): Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials; *J Glaucoma*, 17, 667-673.

Aptel F, Choudhry R, Stalmans I (2016): Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension; *Curr Med Res Opin*, 32, 1457-1463.

Aquino MV, Lat-Luna M (1999): The effect of latanoprost vs timolol on intraocular pressure in patients with glaucoma and ocular hypertension; *Asian J Ophthalmol*, 1, 3-7.

Arcieri ES, Santana A, Rocha FN et al (2005): Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial; *Arch Ophthalmol*, 123, 186-192.

Arend O, Harris A, Wolter P et al (2003): Evaluation of retinal haemodynamics and retinal function after application of dorzolamide, timolol and latanoprost in newly diagnosed open-angle glaucoma patients; *Acta Ophthalmol Scand*, 81, 474-479.

Arias A, Schargel K, Ussa F et al (2010): Patient persistence with first-line antiglaucomatous monotherapy; *Clin Ophthalmol*, 4, 261-267.

Arici MK, Erdogan H, Toker I et al (2006): The effect of latanoprost, bimatoprost, and travoprost on intraocular pressure after cataract surgery; *J Ocul Pharmacol Ther*, 22, 34-40.

- Arranz-Marquez E, Teus MA (2007): Effect of age on the development of a latanoprost-induced increase in iris pigmentation; *Ophthalmology*, 114, 1255-1258.
- Arranz-Marquez E, Teus-Guezala MA, Canseco-Gonzalez F (2002): Respiratory effects of chronic therapy with latanoprost in patients with chronic obstructive pulmonary disease; *Arch Soc Esp Oftalmol*, 77, 553-558.
- Arranz-Marquez E, Teus MA, Saornil MA et al (2004): Analysis of irises with a latanoprost-induced change in iris color; *Am J Ophthalmol*, 138, 625-630.
- Artunay O, Senel A, Sengul A et al (2011): Central serous chorioretinopathy associated with topical latanoprost therapy; *Ocul Immunol Inflamm*, 19, 453-455.
- Aslanides IM (2000): Bilateral optic disc oedema associated with latanoprost; *Br J Ophthalmol*, 84, 673.
- Aung T, Wong HT, Yip CC et al (2000): Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study; *Ophthalmology*, 107, 1178-1183.
- Aung T, Chew PT, Yip CC et al (2001): A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension; *Am J Ophthalmol*, 131, 636-642.
- Aung T, Chew PTK, Oen FTS et al (2002): Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure; *Br J Ophthalmol*, 86, 75-79.
- Avakian A, Renier SA, Butler PJ (1998): Adverse effects of latanoprost on patients with medically resistant glaucoma; *Arch Ophthalmol*, 116, 679-680.
- Aydin Kurna S, Acikgoz S, Altun A et al (2014): The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: a prospective study; *J Ophthalmol*, 2014, 460483.
- Ayyala RS, Cruz DA, Margo CE et al (1998): Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes; *Am J Ophthalmol*, 126, 602-604.
- Babu K, Murthy GJ (2013): Cytomegalovirus anterior uveitis in immunocompetent individuals following topical prostaglandin analogues; *J Ophthalmic Inflamm Infect*, 3, 55.
- Bacharach J, Dubiner HB, Levy B et al (2015): Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure; *Ophthalmology*, 122, 302-307.
- Bafa M, Georgopoulos G, Mihas C et al (2011): The effect of prostaglandin analogues on central corneal thickness of patients with chronic open-angle glaucoma: a 2-year study on 129 eyes; *Acta Ophthalmol*, 89, 448-451.
- Bahler CK, Howell KG, Hann CR et al (2008): Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments; *Am J Ophthalmol*, 145, 114-119.

Baudouin C, Rouland JF, Nordmann JP et al (2006): Efficacy of first- or second line latanoprost on intraocular pressure and ocular symptoms in patients with open-angle glaucoma or ocular hypertension; *J Fr Ophthalmol*, 29, 615-624.

Baudouin C, Renard JP, Nordmann JP et al (2012): Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension; *Eur J Ophthalmol*, 23, 47-54.

Bayer A, Tas A, Sobaci G et al (2002): Efficacy of latanoprost additive therapy on uncontrolled glaucoma; *Ophthalmologica*, 216, 443-448.

Bayer A, Weiler W, Oeverhaus U et al (2004): Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies; *J Ocul Pharmacol Ther*, 20, 470-478.

Bean G, Reardon G, Zimmerman TJ (2004): Association between ocular herpes simplex virus and topical ocular hypotensive therapy; *J Glaucoma*, 13, 361-364.

Beckers HJ, Schouten JS, Webers CA et al (2008): Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction; *Graefes Arch Clin Exp Ophthalmol*, 246, 1485-1490.

Bell NP, Ramos JL, Feldman RM (2010): Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension; *Clin Ophthalmol*, 4, 1331.

Birt CM, Buys YM, Ahmed II et al (2010): Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study); *J Glaucoma*, 19, 460-467.

Black AC, Jones S, Yanovitch TL et al (2009): Latanoprost in pediatric glaucoma--pediatric exposure over a decade; *J AAPOS*, 13, 558-562.

Blume-Peytavi U, Lonnfors S, Hillmann K et al (2012): A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia; *J Am Acad Dermatol*, 66, 794-800.

Bolivar G, Sanchez-Barahona C, Teus M et al (2015): Effect of topical prostaglandin analogues on corneal hysteresis; *Acta Ophthalmol* 93, e495-e498.

Boltz A, Schmidl D, Weigert G et al (2011): Effect of latanoprost on choroidal blood flow regulation in healthy subjects; *Invest Ophthalmol Vis Sci*, 52, 4410-4415.

Brasil OF, Brasil MV, Ventura MP et al (2010): Bilateral and simultaneous cystoid macular edema associated with latanoprost use: report of two cases; *Arq Bras Oftalmol*, 73, 186-188.

Bron AM, Emmerich KH (2002): Latanoprost versus combined timolol and dorzolamide; *Surv Ophthalmol*, 47(Suppl.1), S148-S154.

Bron AM, Denis P, Nordmann JP et al (2001): Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol; *Acta Ophthalmol Scand*, 79, 289-293.

Bron A, et le groupe Europeen d'etudes du latanoprost (European latanoprost study group) (2002): Comparison of latanoprost monotherapy with timolol-dorzolamide combination in patients with open-angle glaucoma or ocular hypertension; *J Fr Ophtalmol*, 25, 604-608.

Bron A, Chiambaretta F, Pouliquen P et al (2003): Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension; *J Fr Ophtalmol*, 26, 668-674.

Browning DJ, Perkins SL, Lark KK (2003): Iris cyst secondary to latanoprost mimicking iris melanoma; *Am J Ophthalmol*, 135, 419-421.

Bucci MG (1999): Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group; *J Glaucoma*, 8, 24-30.

Buguet A, Pv P, Romanet JP (1994): 24-hour (nyctohemeral) and sleep-related variations of intraocular pressure in healthy white individuals; *Am J Ophthalmol*, 117, 342-347.

Calladine D, Harrison RJ (2007): Severe darkening of a facial skin graft from latanoprost; *Arch Ophthalmol*, 125, 1427-1428.

Callanan D, Fellman RL, Savage JA (1998): Latanoprost-associated cystoid macular edema; *Am J Ophthalmol*, 126, 134-135.

Camras CB, The United States Latanoprost Study Group (1996a): Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group; *Ophthalmology*, 103, 138-147.

Camras CB, Alm A, Watson P et al (1996b): Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups; *Ophthalmology*, 103, 1916-1924.

Camras CB, Wax MB, Ritch R et al (1998): Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group; *Am J Ophthalmol*, 126, 390-399.

Camras CB, Neely DG, Weiss EL (2000): Latanoprost-induced iris color darkening: a with long-term follow-up; *J Glaucoma*, 9, 95-98.

Camras CB, Sheu WP, United States Latanoprost-Brimonidine Study Group (2005): Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States; *J Glaucoma*, 14, 161-167.

Cardascia N, Vetrugno M, Trabucco T et al (2003): Effects of travoprost eye drops on intraocular pressure and pulsatile ocular blood flow: a 180-day, randomized, double-masked comparison with latanoprost eye drops in patients with open-angle glaucoma; *Curr Ther Res*, 64, 389-400.

Casson RJ, Selva D (2005): Lash ptosis caused by latanoprost; *Am J Ophthalmol*, 139, 932-933.

Chae B, Cakiner-Egilmez T, Desai M (2013): Glaucoma medications; *Insight*, 38, 5-9.

Chang L, Ong EL, Bunce C et al (2013): A review of the medical treatment of pediatric glaucomas at Moorfields Eye Hospital; *J Glaucoma*, 22, 601-607.

Chen CS, Wells J, Craig JE (2004): Topical prostaglandin F(2alpha) analog induced poliosis; *Am J Ophthalmol*, 137, 965-966.

Chen MJ, Chen YC, Chou CK et al (2006): Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle-closure glaucoma; *J Ocul Pharmacol Ther*, 22, 449-454.

Chen MJ, Chen YC, Chou CK et al (2007): Comparison of the effects of latanoprost and bimatoprost on intraocular pressure in chronic angle-closure glaucoma; *J Ocul Pharmacol Ther*, 23, 559-566.

Chen R, Yang K, Zheng Z et al (2016): Meta-analysis of the efficacy and safety of latanoprost monotherapy in patients with angle-closure glaucoma; *J Glaucoma*, 25, e134-e144.

Cheng JW, Wei RL (2008): Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure; *Clin Ther*, 30, 622-632.

Cheng JW, Xi GL, Wei RL et al (2009a): Efficacy and tolerability of latanoprost compared to dorzolamide combined with timolol in the treatment of patients with elevated intraocular pressure: a meta-analysis of randomized, controlled trials; *J Ocul Pharmacol Ther*, 25, 55-64.

Cheng JW, Li Y, Wei RL (2009b): Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost; *Ophthalmic Res*, 42, 99-105.

Cheng JW, Cai JP, Wei RL (2009c): Meta-analysis of medical intervention for normal tension glaucoma; *Ophthalmology*, 116, 1243-1249.

Chew PTK, Hung PT, Aung T (2002): Efficacy of latanoprost in reducing intraocular pressure in patients with primary angle-closure glaucoma; *Surv Ophthalmol*, 47(Suppl.1), S125-S128.

Chew PT, Aung T, Aquino MV et al (2004): Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma; *Ophthalmology*, 111, 427-434.

Chiba T, Kashiwagi K, Kogure S et al (2001): Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients; *J Glaucoma*, 10, 406-410.

Chiba T, Kashiwagi K, Ishijima K et al (2004): A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost; *Jpn J Ophthalmol*, 48, 141-147.

Chiba T, Kashiwagi K, Chiba N et al (2006): Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open angle glaucoma or ocular hypertension; *Br J Ophthalmol*, 90, 314-317.

Chien KH, Lu DW, Chen JT (2009): Extensive facial skin pigmentation after latanoprost treatment; *Cutan Ocul Toxicol*, 28, 185-187.

Chou SY, Chou CK, Kuang TM et al (2005): Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes; *Eye*, 19, 784-787.

- Connor AJ, Fraser SG (2014): Glaucoma prescribing trends in England 2000 to 2012; *Eye*, 28, 863-869.
- Coronel-Perez IM, Rodriguez-Rey EM, Camacho-Martinez FM (2010): Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis; *J Eur Acad Dermatol Venereol*, 24, 481-485.
- Costagliola C, Prete AD, Incorvaia C et al (2001): Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis; *Graefes Arch Clin Exp Ophthalmol*, 239, 809-814.
- Costagliola C, Del Prete A, Verolino M et al (2002): Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients; *Graefes Arch Clin Exp Ophthalmol*, 240, 379-386.
- Costagliola C, Parmeggiani F, Virgili G et al (2008): Circadian changes of intraocular pressure and ocular perfusion pressure after timolol or latanoprost in Caucasians with normal-tension glaucoma; *Graefes Arch Clin Exp Ophthalmol*, 246, 389-396.
- Cracknell KP, Grierson I, Hogg P et al (2003): Latanoprost-induced iris darkening: a morphometric study of human peripheral iridectomies; *Exp Eye Res*, 77, 721-730.
- Cracknell KP, Grierson I, Hogg P (2007a): Morphometric effects of long-term exposure to latanoprost; *Ophthalmology*, 114, 938-948.
- Cracknell KP, Farnell DJ, Grierson I (2007b): Monte Carlo simulation of latanoprost induced iris darkening; *Comput Methods Programs Biomed*, 87, 93-103.
- Crichton AC, Vold S, Williams JM et al (2013): Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension; *Adv Ther*, 30, 260-270.
- Cucherat M, Stalmans I, Rouland JF (2014): Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials; *J Glaucoma*, 23, e69-e75.
- Cui XJ, Zhao AG, Wang XL (2017): Correlations of AFAP1, GMDS and PTGFR gene polymorphisms with intra-ocular pressure response to latanoprost in patients with primary open-angle glaucoma; *J Clin Pharm Ther*, 42, 87-92.
- Daka Q, Trkulja V (2014): Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews; *Croat Med J*, 55, 468-480.
- Day DG, Walters TR, Schwartz GF et al (2013): Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial; *Br J Ophthalmol*, 97, 989-993.
- De Santis M, Lucchese A, Carducci B et al (2004): Latanoprost exposure in pregnancy; *Am J Ophthalmol*, 138, 305-306.
- De Smit E, Theodorou M, Hildebrand GD et al (2011): Heart block following topical latanoprost treatment; *BMJ Case Rep*, 2011, bcr0820114607.

Deai T, Fukuda M, Hibino T et al (2004): Herpes simplex virus genome quantification in two patients who developed herpetic epithelial keratitis during treatment with antiglaucoma medications; *Cornea*, 23, 125-128.

Demitsu T, Manabe M, Harima N et al (2001): Hypertrichosis induced by latanoprost; *J Am Acad Dermatol*, 44, 721-723.

Denis P, Lafuma A, Khoshnood B et al (2007): A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy; *Curr Med Res Opin*, 23, 601-608.

Denis P, Baudouin C, Bron A et al (2010): First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure; *BMC Ophthalmol*, 10, 4.

DesMarchais B, Candal E, Weitzman M et al (2000): Effect of latanoprost as adjunctive therapy; *Can J Ophthalmol*, 35, 214-217.

Diestelhorst M (2000): The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group; *Graefes Arch Clin Exp Ophthalmol*, 238, 433-439.

Diestelhorst M, Roters S, Krieglstein GK (1997): The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%; *Graefes Arch Clin Exp Ophthalmol*, 235, 20-26.

Digiuni M, Fogagnolo P, Rossetti L (2012): A review of the use of latanoprost for glaucoma since its launch; *Expert Opin Pharmacother*, 13, 723-745.

Dios-Castro E, Maquet-Dusart JA (2000): Latanoprost-associated recurrent herpes simplex keratitis; *Arch Soc Esp Oftalm*, 11, 1-3.

Dirks MS, Noecker RJ, Earl M et al (2006): A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma; *Adv Ther*, 23, 385-394.

Doi LM, Melo LAS, Prata JA (2005): Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomised clinical trial; *Br J Ophthalmol*, 89, 547-549.

Drance SM, Crichton A, Mills RP (1998): Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma; *Am J Ophthalmol*, 125, 585-592.

DuBiner HB, Mroz M, Shapiro AM et al (2001a): A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial; *Clin Ther*, 23, 1969-1983.

- DuBiner H, Cooke D, Dirks M et al (2001b): Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost; *Surv Ophthalmol*, 45(Suppl.4), S353-S360.
- Einarson TR, Kulin NA, Tingey D et al (2000): Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma; *Clin Ther*, 22, 1502-1515.
- Eisenberg DL, Camras CB (1999): A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension; *Drug Safety*, 20, 505-514.
- Ekatomatis P (2001): Herpes simplex dendritic keratitis after treatment with latanoprost for primary open-angle glaucoma; *Br J Ophthalmol*, 85, 1008-1009.
- Elgin U, Batman A, Berker N et al (2006): The comparison of eyelash lengthening effect of latanoprost therapy in adults and children; *Eur J Ophthalmol*, 16, 247-250.
- Emmerich KH (2000): Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3-month randomised study; *Graefes Arch Clin Exp Ophthalmol*, 238, 19-23.
- Enyedi LB, Freedman SF (2002): Latanoprost for the treatment of pediatric glaucoma; *Surv Ophthalmol*, 47(Suppl.1), S129-S132.
- Enyedi LB, Freedman SF, Buckley EG (1999): The effectiveness of latanoprost for the treatment of pediatric glaucoma; *J AAPOS*, 3, 33-39.
- Ergin A, Ornek K, Gullu R et al (2009): Effects of timolol and latanoprost on respiratory and cardiovascular status in elderly patients with glaucoma; *J Ocul Pharmacol Ther*, 25, 463-466.
- Erkin EF, Celik P, Kayikcioglu O et al (2006): Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients; *Ophthalmologica*, 220, 332-337.
- Esaki Y, Shimazaki A, Pellinen P (2016): Ocular tolerability of preservative-free tafluprost and latanoprost: in vitro and in vivo comparative study; *Open Ophthalmol J*, 10, 146.
- European Glaucoma Society (2008): Terminology and guidelines for glaucoma; *Assessed online at: www.eugs.org/eng/EGS_guidelines.asp* .
- Eveleth D, Starita C, Tressler C (2012): A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 µg/mL to latanoprost 50 µg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension; *BMC Ophthalmol*, 12, 9.
- Eyawo O, Nachege J, Lefebvre P et al (2009): Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis; *Clin Ophthalmol*, 3, 447-456.
- Fahim A, Morice AH (2009): Heightened cough sensitivity secondary to latanoprost; *Chest*, 136, 1406-1407.
- Faridi UA, Saleh TA, Ewings P et al (2010): Comparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension, open-angle and normal tension glaucoma; *Clin Experiment Ophthalmol*, 38, 678-682.

Fechtner RD, Khouri AS, Zimmerman TJ et al (1998): Anterior uveitis associated with latanoprost; *Am J Ophthalmol*, 126, 37-41.

Feldman RM (2003): Conjunctival hyperaemia and the use of topical prostaglandins in glaucoma and ocular hypertension; *J Ocul Pharmacol Ther*, 19, 23-35.

Florez A, Roson E, Conde A et al (2005): Toxic epidermal necrolysis secondary to timolol, dorzolamide, and latanoprost eyedrops; *J Am Acad Dermatol*, 53, 909-911.

Fristrom B (1996): A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension; *Acta Ophthalmol Scand*, 74, 140-144.

Fristrom B, Nilsson SE (1993): Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine: A study on patients with elevated intraocular pressure; *Arch Ophthalmol*, 111, 662-665.

Fristrom B, Nilsson SE (1997): A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension; *Br J Ophthalmol*, 81, 867-870.

Fristrom B, Uusitalo H (2010): A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension; *Acta Ophthalmol*, 88, 37-43.

Fung AT, Reid SE, Jones MP et al (2007): Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma; *Br J Ophthalmol*, 91, 62-68.

Furuichi M, Chiba T, Abe K et al (2001): Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier; *J Glaucoma*, 10, 233-236.

Gandolfi S, Simmons ST, Sturm R et al (2001): Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension; *Adv Ther*, 18, 110-121.

Gao LC, Wang D, Liu FQ et al (2015): Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients; *Eur J Clin Pharmacol*, 71, 43-50.

Garcia Sanchez J (2000): Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group; *Eur J Ophthalmol*, 10, 198-204.

Garcia-Feijoo J, Martínez-de-la-Casa JM, Castillo A et al (2006): Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%; *Curr Med Res Opin*, 22, 1689-1697.

Garway-Heath DF, Crabb DP, Bunce C et al (2015): Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial; *Lancet*, 385, 1295-1304.

Georgopoulos GT, Diestelhorst M, Fisher R et al (2002): The short-term effect of latanoprost on intraocular pressure and pulsatile ocular blood flow; *Acta Ophthalmol Scand*, 80, 54-58.

Geyer O, Man O, Weintraub M et al (2001): Acute effect of latanoprost on pulsatile ocular blood flow in normal eyes; *Am J Ophthalmol*, 131, 198-202.

Gherghel D, Hosking SL, Cunliffe IA et al (2008): First-line therapy with latanoprost 0.005% results in improved ocular circulation in newly diagnosed primary open-angle glaucoma patients: a prospective, 6-month, open-label study; *Eye*, 22, 363-369.

Goldberg I, Li XY, Selaru P et al (2008): A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension; *Eur J Ophthalmol*, 18, 408-416.

Goto Y, Ibaraki N, Miyake K (2003): Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol; *Arch Ophthalmol*, 121, 835-839.

Grierson I, Lee WR, Albert DM (1999): The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change; *Arch Ophthalmol*, 117, 394-396.

Grierson I, Jonsson M, Cracknell K (2004): Latanoprost and pigmentation; *Jpn J Ophthalmol*, 48, 602-612.

Grigoropoulos VG, Emfietzoglou I, Nikolaidis P et al (2009): Cystoid macular oedema within 24 h after a single application of latanoprost; *Int Ophthalmol*, 29, 257-259.

Guedes RA, Guedes VM, Freitas SM et al (2012): Quality of life of glaucoma patients under medical therapy with different prostaglandins; *Clin Ophthalmol*, 6, 1749-1753.

Guenoun JM, Baudouin C, Rat P et al (2005): In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells; *Invest Ophthalmol Vis Sci*, 46, 2444-2450.

Gulati V, Fan S, Zhao M et al (2012): Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy; *Arch Ophthalmol*, 130, 677-684.

Gutierrez-Diaz E, Silva Cotta J, Munoz-Negrete FJ et al (2014): Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study; *Clin Ophthalmol*, 8, 725-732.

Hamacher T, Airaksinen J, Saarela V et al (2008): Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis; *Acta Ophthalmol Suppl*, 242, 14-19.

Hamard P, Blondin C, Debbasch C et al (2003): In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells; *Graefes Arch Clin Exp Ophthalmol*, 241, 1037-1043.

Haneda M, Shirato S, Maruyama K et al (2006): Comparison of the additive effects of nipradilol and carteolol to latanoprost in open-angle glaucoma; *Jpn J Ophthalmol*, 50, 33-37.

Hara (2001): Increased iris pigmentation after use of latanoprost in Japanese brown eyes; *Nippon Ganka Gakkai Zasshi*, 105, 314-321.

Harris A, Garzozzi HJ, McCranor L et al (2009): The effect of latanoprost on ocular blood flow; *Int Ophthalmol*, 29, 19-26.

Hatanaka M, Reis A, Sano ME et al (2010): Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial; *J Glaucoma*, 19, 331-335.

Haverkamp F, Wuensch S, Fuchs M et al (2004): Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments; *Eur J Ophthalmol*, 14, 407-415.

Hedman K, Alm A (2000): A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol; *Eur J Ophthalmol*, 10, 95-104.

Hedman K, Watson PG, Alm A (2002): The effect of latanoprost on intraocular pressure during 2 years of treatment; *Surv Ophthalmol*, 47(Suppl.1), S65-S76.

Hedman K, Alm A, Gross RL (2003): Pooled-data analysis of three randomized, double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension; *J Glaucoma*, 12, 463-465.

Hedner J, Svedmyr N, Lunde H et al (1997): The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma; *Surv Ophthalmol*, 41(Suppl.2), S111-S115.

Hedner J, Everts B, Moller CS (1999): Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation; *Arch Ophthalmol*, 117, 1305-1309.

Heier JS, Steinert RF, Frederick AR (1998): Cystoid macular edema associated with latanoprost use; *Arch Ophthalmol*, 116, 680-682.

Herndon LW, Williams RD, Wand M et al (2003): Increased periocular pigmentation with ocular hypotensive lipid use in African Americans; *Am J Ophthalmol*, 135, 713-715.

Higginbotham EJ, Diestelhorst M, Pfeiffer N et al (2002): The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications; *Surv Ophthalmol*, 47(Suppl.1), S133-S140.

Hinz B, Rosch S, Ramer R et al (2005): Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism; *FASEB J*, 19, 1929-1931.

Hodge WG, Lachaine J, Steffensen I et al (2008): The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review; *Br J Ophthalmol*, 92, 7-12.

Holmstrom S, Buchholz P, Walt J et al (2005): Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma; *Curr Med Res Opin*, 21, 1875-1883.

Honda N, Miyai T, Nejima R et al (2010): Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface; *Arch Ophthalmol*, 128, 466-471.

Honrubia FM, Larsson LI, Spiegel D et al (2002): A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma; *Acta Ophthalmol Scand*, 80, 635-641.

Honrubia F, Garcia-Sanchez J, Polo V et al (2009): Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomized clinical trials; *Br J Ophthalmol*, 93, 316-321.

How AC, Kumar RS, Chen YM et al (2009): A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma; *Br J Ophthalmol*, 93, 782-786.

Hung PT, Hsieh JW, Chen YF et al (2000): Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy; *J Ocul Pharmacol Ther*, 16, 43-47.

Hylton C, Robin AL (2003): Update on prostaglandin analogs; *Curr Opin Ophthalmol*, 14, 65-69.

Ikeda Y, Mori K, Tada K et al (2016): Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma; *Clin Ophthalmol*, 10, 1633-1637.

Imasawa M, Tanabe J, Kashiwagi F et al (2016): Efficacy and safety of switching latanoprost monotherapy to bimatoprost monotherapy or combination of brinzolamide and latanoprost; *Open Ophthalmol J*, 10, 94-102.

Inan UU, Ermis SS, Yucel A et al (2003): The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial; *Acta Ophthalmol Scand*, 81, 155-160.

Inoue K, Wakakura M, Inoue J et al (2006): Adverse reaction after use of latanoprost in Japanese glaucoma patients; *Nippon Ganka Gakkai Zasshi*, 110, 581-587.

Inoue K, Shiokawa M, Higa R et al (2012): Adverse periocular reactions to five types of prostaglandin analogs; *Eye*, 26, 1465-1472.

Inoue K, Shiokawa M, Wakakura M et al (2013): Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs; *J Glaucoma*, 22, 626-631.

Ishii K, Tomidokoro A, Nagahara M et al (2001): Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans; *Invest Ophthalmol Vis Sci*, 42, 2957-2963.

Italian Multicentric Study (2000): Hypotensive efficacy in primary open-angle glaucoma and ocular hypertension: latanoprost in monotherapy vs timolol and dorzolamine in association; *Acta Ophthalmol Scand Suppl*, 78, 49-50.

Ito K, Goto R, Matsunaga K et al (2004): Switch to latanoprost monotherapy from combined treatment with beta-antagonist and other antiglaucoma agents in patients with glaucoma or ocular hypertension; *Jpn J Ophthalmol*, 48, 276-280.

- Jaenen N, Baudouin C, Pouliquen P et al (2007): Ocular symptoms and signs with preserved and preservative-free glaucoma medications; *Eur J Ophthalmol*, 17, 341-349.
- Jager M, Jonas JB (2003): Cystoid macular edema associated with latanoprost therapy in a pseudophakic vitrectomized patient after removal of silicone oil endotamponade; *Eur J Ophthalmol*, 13, 221-222.
- Jampel HD, Bacharach J, Sheu WP et al (2002): Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure; *Am J Ophthalmol*, 134, 863-871.
- Jerstad KM, Warshaw E (2002): Allergic contact dermatitis to latanoprost; *Am J Contact Dermat*, 13, 39-41.
- Johnson TV, Fan S, Zhan G et al (2010): Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment; *J Glaucoma*, 19, 356-364.
- Johnstone MA (1997): Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost; *Am J Ophthalmol*, 124, 544-547.
- Johnstone MA, Albert DM (2002): Prostaglandin-induced hair growth; *Surv Ophthalmol*, 47(Suppl.1), S185-S202.
- Kahook MY, Ammar DA (2010): In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells; *J Ocul Pharmacol Ther*, 26, 259-263.
- Kalouche G, Beguier F, Bakria M et al (2016): Activation of prostaglandin FP and EP2 receptors differently modulates myofibroblast transition in a model of adult primary human trabecular meshwork cells FP and EP2 receptor effects on trabecular meshwork cells; *IOVS*, 57, 1816-1825.
- Kaluzny J, Sobiecki R, Czechowicz-Janicka K et al (2008): Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension; *Acta Ophthalmol*, 86, 860-865.
- Kampik A, Arias-Puente A, O'Brart DP et al (2002): Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study; *J Glaucoma*, 11, 90-96.
- Kara C, Sen EM, Elgin KU et al (2016): Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term?; *Int Ophthalmol*, Epub ahead of print.
- Karslioglu MZ, Hosal MB, Tekeli O (2015): Periocular changes in topical bimatoprost and latanoprost use; *Turk J Med Sci*, 45, 925-930.
- Kashiwagi K, Tsukahara S (2003): Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost; *Br J Ophthalmol*, 87, 297-301.
- Katz LJ, Rauchman SH, Cottingham AJ et al (2012): Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study; *Curr Med Res Opin*, 28, 781-788.

- Kawaguchi I, Higashide T, Ohkubo S et al (2012): Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects; *Jpn J Ophthalmol*, 56, 346-353.
- Kerstetter JR, Brubaker RF, Wilson SE et al (1988): Prostaglandin F2 α -1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow; *Am J Ophthalmol*, 105, 30-34.
- Kim HJ, Cho BJ (2011): Long-term effect of latanoprost on central corneal thickness in normal tension glaucoma; *J Ocul Pharmacol Ther*, 27, 73-76.
- Kim JW, Lindsey JD, Wang N et al (2001): Increased human scleral permeability with prostaglandin exposure; *Invest Ophthalmol Vis Sci*, 42, 1514-1521.
- Kim EJ, Kim YH, Kang SH et al (2013): In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells; *Korean J Ophthalmol*, 27, 446-453.
- Kim YK, Na KI, Jeoung JW et al (2017): Intraocular pressure-lowering effect of latanoprost is hampered by defective cervical lymphatic drainage; *PLoS One*, 12, e0169683.
- Kjellgren D, Douglas G, Mikelberg FS et al (1995): The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma; *Acta Ophthalmol Scand*, 73, 233-236.
- Kobayashi H (2012a): Efficacy of single glaucoma medication in combined latanoprost and timolol XE therapy in patients with open-angle glaucoma and ocular hypertension: a discontinuation study; *J Ocul Pharmacol Ther*, 28, 387-391.
- Kobayashi H (2012b): Efficacy of single glaucoma drug in combined timolol XE, latanoprost and brinzolamide therapy: a discontinuation study; *J Ocul Pharmacol Ther*, 28, 245-250.
- Kobayashi H, Kobayashi K (2011): A correlation between latanoprost-induced conjunctival hyperemia and intraocular pressure-lowering effect; *J Glaucoma*, 20, 3-6.
- Kobayashi H, Kobayashi K, Okinami S (2004): Efficacy of bunazosin hydrochloride 0.01% as adjunctive therapy of latanoprost or timolol; *J Glaucoma*, 13, 73-80.
- Koh SW, Coll TJ, Rose L et al (2004): Antiglaucoma eye drop pulses--increased interleukin-6 secretion by Tenon's capsule fibroblast cultures; *J Glaucoma*, 13, 200-209.
- Konstas AG, Maltezos AC, Gandi S et al (1999): Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma; *Am J Ophthalmol*, 128, 15-20.
- Konstas AG, Lake S, Maltezos AC et al (2001): Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma; *Eye*, 15, 59-62.
- Konstas AG, Kozobolis VP, Tersis I et al (2003): The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma; *Eye*, 17, 41-46.
- Konstas AG, Mylopoulos N, Karabatsas CH et al (2004): Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma; *Eye*, 18, 893-899.

Konstas AG, Karabatsas CH, Lallos N et al (2005): 24-hour intraocular pressure with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects; *Ophthalmology*, 112, 603-608.

Konstas AG, Holló G, Irkeç M et al (2007): Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study; *Br J Ophthalmol*, 91, 757-760.

Konstas AG, Kozobolis VP, Tsironi S et al (2008): Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment; *Ophthalmology*, 115, 99-103.

Konstas AG, Quaranta L, Katsanos A et al (2013): Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension; *Br J Ophthalmol*, 97, 1510-1515.

Kook MS, Lee K (2000): Increased eyelid pigmentation associated with use of latanoprost; *Am J Ophthalmol*, 129, 804-806.

Korobko IV, Lomonosov KM (2016): A pilot comparative study of topical latanoprost and tacrolimus in combination with narrow-band ultraviolet B phototherapy and microneedling for the treatment of nonsegmental vitiligo; *Dermatol Ther*, 29, 437-441.

Koz OG, Ozsoy A, Yarangumeli A et al (2007): Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial; *Acta Ophthalmol Scand*, 85, 838-843.

Kozobolis VP, Detorakis ET, Maskaleris G et al (2005): Corneal sensitivity changes following the instillation of latanoprost, bimatoprost, and travoprost eyedrops; *Am J Ophthalmol*, 139, 742-743.

Kraft ME, Glaeser H, Mandery K et al (2010): The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost; *Invest Ophthalmol Vis Sci*, 51, 2504-2511.

Kremmer S, Iliadou M, Anastassiou G et al (2014): Influence of latanoprost on retinal microcirculation in glaucoma; *Open Ophthalmol J*, 8, 60-66.

Krishnamurthy R, Senthil S, Garudadri CS (2015): Late postoperative choroidal detachment following an uneventful cataract surgery in a patient on topical latanoprost; *BMJ Case Rep*, 2015, bcr2015211408.

Krohn J, Hove VK (1999): Iris cyst associated with topical administration of latanoprost; *Am J Ophthalmol*, 127, 91-93.

Kuba GB, Kurnatowski-Billion M, Neuser AM et al (2001): Effect of latanoprost on ocular hemodynamics and contrast sensitivity; *Ophthalmologe*, 98, 535-540.

Kucukevcilioglu M, Bayer A, Uysal Y et al (2014): Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost; *Clin Experiment Ophthalmol*, 42, 126-131.

Kumar S, Malik A, Singh M et al (2009): Efficacy of latanoprost in management of chronic angle closure glaucoma; *Nepal J Ophthalmol*, 1, 32-36.

Lai JS, Chua JK, Leung AT et al (2000): Latanoprost versus timolol gel to prevent ocular hypertension after phacoemulsification and intraocular lens implantation; *J Cataract Refract Surg*, 26, 386-391.

Lai JS, Loo A, Tham CC et al (2001): Preoperative latanoprost to prevent ocular hypertension after phacoemulsification and intraocular lens implantation; *J Cataract Refract Surg*, 27, 1792-1795.

Lai IC, Kuo MT, Teng IMC (2003): Iris pigment epithelial cyst induced by topical administration of latanoprost; *Br J Ophthalmol*, 87, 366.

Lai CH, Lai IC, Chi CC (2006): Allergic contact dermatitis caused by latanoprost ophthalmic solution; *Eur J Ophthalmol*, 16, 627-629.

Larsson LI (2001a): Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study; *Acta Ophthalmol Scand*, 79, 567-571.

Larsson LI (2001b): Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension; *Ophthalmology*, 108, 1439-1444.

Larsson LI, Mishima HK, Takamatsu M et al (2002): The effect of latanoprost on circadian intraocular pressure; *Surv Ophthalmol*, 47(Suppl.1), S90-S96.

Lass JH, Eriksson GL, Osterling L et al (2001): Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: A double-masked, randomized, one-year study; *Ophthalmology*, 108, 264-271.

Latanoprost-Induced Iris Pigmentation Study Group (2006): Incidence of latanoprost-induced increase in iris pigmentation in Japanese eyes; *Jpn J Ophthalmol*, 50, 96-99.

Lee H, Cho BJ (2015): Long-term effect of latanoprost on central corneal thickness in normal-tension glaucoma: five-year follow-up results; *J Ocul Pharmacol Ther*, 31, 152-155.

Lee S, Kim MK, Choi HJ et al (2013): Comparative cross-sectional analysis of the effects of topical antiglaucoma drugs on the ocular surface; *Adv Ther*, 30, 420-429.

Lee JH, Kim TH, Kim SC (2014): Allergic contact dermatitis caused by topical eye drops containing latanoprost; *Ann Dermatol*, 26, 269-270.

Lee NY, Park HY, Park CK (2016): Comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and ocular perfusion pressure in patients with normal-tension glaucoma: a randomized, crossover clinical trial; *PLoS One*, 11, e0146680.

Leng F, Liu P, Li H et al (2011): Long-term topical antiglaucoma medications cause enhanced Tenon's capsule fibroblast proliferation and abnormal TGF- β and MMP expressions: potential effects on glaucoma filtering surgery; *Curr Eye Res*, 36, 301-309.

Li N, Chen XM, Zhou Y et al (2006): Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials; *Clin Experiment Ophthalmol*, 34, 755-764.

Li SM, Chen R, Li Y et al (2014): Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma; *PLoS One*, 9, e96852.

Li T, Lindsley K, Rouse B et al (2016): Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis; *Ophthalmology*, 123, 129-140.

Liang H, Brignole-Baudouin F, Pauly A et al (2011): Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study; *Adv Ther*, 28, 311-325.

Lim KS, Nau CB, O'Byrne MM et al (2008): Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study; *Ophthalmology*, 115, 790.e4-795.e4.

Lima MC, Paranhos A, Salim S et al (2000): Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost; *J Glaucoma*, 9, 317-321.

Lin L, Zhao YJ, Chew PT et al (2014): Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension; *Ann Pharmacother*, 48, 1585-1593.

Linden C, Alm A (1997): Effects on intraocular pressure and aqueous flow of various dose regimens of latanoprost in human eyes; *Acta Ophthalmol Scand*, 75, 412-415.

Linden C, Alm A (1998): Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity?; *Curr Eye Res*, 17, 567-572.

Linden C, Alm A (2001): The effect on intraocular pressure of latanoprost once or four times daily; *Br J Ophthalmol*, 85, 1163-1166.

Linden C, Nuija E, Alm A (1997): Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension; *Br J Ophthalmol*, 81, 370-372.

Lindsey JD, To HD, Weinreb RN (1994): Induction of c-fos by prostaglandin F2 alpha in human ciliary smooth muscle cells; *Invest Ophthalmol Vis Sci*, 35, 242-250.

Lindsey JD, Jones HL, Hewitt EG et al (2001): Induction of tyrosinase gene transcription in human iris organ cultures exposed to latanoprost; *Arch Ophthalmol*, 119, 853-60.

Liu CJ, Ko YC, Cheng CY et al (2002a): Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma; *Br J Ophthalmol*, 86, 1236-1239.

Liu CJ, Ko YC, Cheng CY et al (2002b): Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients; *Ophthalmology*, 109, 2241-2247.

Liu CJ, Cheng CY, Chiang SC et al (2002c): Use of latanoprost to reduce acute intraocular pressure rise following neodymium: Yag laser iridotomy; *Acta Ophthalmol Scand*, 80, 282-286.

- Liu Y, Yanai R, Lu Y et al (2006): Effects of antiglaucoma drugs on collagen gel contraction mediated by human corneal fibroblasts; *J Glaucoma*, 15, 255-259.
- Liu Y, Ko JA, Yanai R et al (2008): Induction by latanoprost of collagen gel contraction mediated by human tenon fibroblasts: role of intracellular signaling molecules; *IOVS*, 49, 1429-1436.
- Liu JH, Medeiros FA, Slight JR et al (2009): Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy; *Ophthalmology*, 116, 449-454.
- Liu Y, Liu Y, Xu D et al (2015): Latanoprost-induced cytokine and chemokine release from human tenon's capsule fibroblasts: role of MAPK and NF- κ B Signaling pathways; *J Glaucoma*, 24, 635-641.
- Liu H, Yang ZK, Li Y et al (2016): ABCB1 variants confer susceptibility to primary open-angle glaucoma and predict individual differences to latanoprost treatment; *Biomed Pharmacother*, 80, 115-120.
- Lou H, Zong Y, Ge YR et al (2014): Efficacy and tolerability of latanoprost compared with timolol in the treatment of patients with chronic angle-closure glaucoma; *Curr Med Res Opin*, 30, 1367-1373.
- Lupinacci AP, Netland PA, Fung KH et al (2008): Comparison of twice-daily and three-times-daily dosing of dorzolamide in ocular hypertension and primary open-angle glaucoma patients treated with latanoprost; *Adv Ther*, 25, 231-239.
- Luque-Aranda R, Cabarga Del Nozal C, Silva-Silva G et al (2002): Study on hypotensive effect of latanoprost vs timolol-dorzolamide association; *Arch Soc Esp Oftalmol*, 4, 1-7.
- Lusky M, Ticho U, Glovinsky J et al (1997): A comparative study of two dose regimens of latanoprost in patients with elevated intraocular pressure; *Ophthalmology*, 104, 1720-1724.
- Luu ST, Lee AW, Chen CS (2009): Transient monocular visual loss following administration of topical latanoprost: a case report; *Can J Ophthalmol*, 44, 715.
- Luu KT, Raber SR, Nickens DJ et al (2010): A model-based meta-analysis of the effect of latanoprost chronotherapy on the circadian intraocular pressure of patients with glaucoma or ocular hypertension; *Clin Pharmacol Ther*, 87, 421-425.
- Maeda-Chubachi T, Chi-Burris K, Simons BD et al (2011): Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study; *Ophthalmology*, 118, 2014-2021.
- Maeda-Chubachi T, Chi-Burris K, Simons B et al (2013): Impact of age, diagnosis, and history of glaucoma surgery on outcomes in pediatric patients treated with latanoprost; *J Glaucoma*, 22, 614-619.
- Malvitte L, Montange T, Vejux A et al (2007): Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs; *Br J Ophthalmol*, 91, 29-32.
- Marchini G, Ghilotti G, Bonadimani M et al (2003): Effects of 0.005% latanoprost on ocular anterior structures and ciliary body thickness; *J Glaucoma*, 12, 295-300.

Markomichelakis NN, Kostakou A, Halkiadakis I et al (2009): Efficacy and safety of latanoprost in eyes with uveitic glaucoma; *Graefes Arch Clin Exp Ophthalmol*, 247, 775-780.

Marques-Pereira ML, Katz LJ (2001): Choroidal detachment after the use of topical latanoprost; *Am J Ophthalmol*, 132, 928-929.

Maruyama K, Shirato S (2006): Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial; *J Glaucoma*, 15, 341-345.

Maruyama K, Shirato S, Haneda M (2005): Evaluation of the additive effect of bunazosin on latanoprost in primary open-angle glaucoma; *Jpn J Ophthalmol*, 49, 61-62.

Maruyama Y, Mori K, Ikeda Y et al (2014): Effects of long-term topical prostaglandin therapy on central corneal thickness; *J Ocul Pharmacol Ther*, 30, 440-444.

Mastropasqua L, Carpineto P, Ciancaglini M et al (1999): A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma; *Ophthalmology*, 106, 550-555.

Maul E, Carrasco FG, Costa VP et al (2007): A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%; *Clin Ther*, 29, 1915-1923.

McAlinden C (2014): Selective laser trabeculoplasty (SLT) vs other treatment modalities for glaucoma: systematic review; *Eye*, 28, 249-258.

McKibbin M, Menage MJ (1999): The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma; *Eye*, 13, 31-34.

Mishima HK, Masuda K, Kitazawa Y et al (1996): A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study; *Arch Ophthalmol*, 114, 929-932.

Mishima HK, Kiuchi Y, Takamatsu M et al (1997): Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow; *Surv Ophthalmol*, 41(Suppl.2), S139-S144.

Mishra D, Sinha BP, Kumar MS (2014): Comparing the efficacy of latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%), and timolol (0.5%) in the treatment of primary open angle glaucoma; *Korean J Ophthalmol*, 28, 399-407.

Mitra M, Chang B, James T (2001): Exacerbation of angina associated with latanoprost; *BMJ*, 323, 783.

Miura K, Ito K, Okawa C et al (2008): Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost; *J Glaucoma*, 17, 233-237.

Miyake K, Ibaraki N (2002): Prostaglandins and cystoid macular edema; *Surv Ophthalmol*, 47(Suppl.1), S203-S218.

Miyake K, Ota I, Maekubo K et al (1999): Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias; *Arch Ophthalmol*, 117, 34-40.

Mochizuki H, Itakura H, Yokoyama T et al (2010): Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects; *Jpn J Ophthalmol*, 54, 286-290.

Morales J, Shihab ZM, Brown SM et al (2001): Herpes simplex virus dermatitis in patients using latanoprost; *Am J Ophthalmol*, 132, 114-116.

Moroi SE, Gottfredsdottir MS, Schteingart MT et al (1999): Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension; *Ophthalmology*, 106, 1024-1029.

Mulaney J, Sonty S, Ahmad A et al (2008): Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost; *Eur J Ophthalmol*, 18, 556-562.

Nagasubramanian S, Sheth GP, Hitchings RA et al (1993): Intraocular pressure-reducing effect of PhAX41 in ocular hypertension: comparison of dose regimens; *Ophthalmology*, 100, 1305-1311.

Nakakura S, Tabuchi H, Kiuchi Y (2011): Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost; *Optom Vis Sci*, 88, 1140-1144.

Nakakura S, Yamamoto M, Terao E et al (2014): Prostaglandin-associated periorbitopathy in latanoprost users; *Clin Ophthalmol*, 9, 51-56.

Nakamura Y, Ishikawa S, Nakamura Y et al (2009): 24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost; *Clin Ophthalmol*, 3, 395-400.

Netland PA, Landry T, Sullivan EK et al (2001): Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension; *Am J Ophthalmol*, 132, 472-484.

Nicolela MT, Buckley AR, Walman BE et al (1996a): A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels; *Am J Ophthalmol*, 122, 784-789.

Nicolela MT, Walman BE, Buckley AR et al (1996b): Ocular hypertension and primary open-angle glaucoma: a comparative study of their retrobulbar blood flow velocity; *J Glaucoma*, 5, 308-310.

Nilforushan N, Naghibi A, Shokrollahi S et al (2012): Intraocular pressure-lowering effect of 0.005% latanoprost with two different dosing regimens; *J Ocul Pharmacol Ther*, 28, 524-528.

Noecker RS, Dirks MS, Choplin NT et al (2003): A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma; *Am J Ophthalmol*, 135, 55-63.

Nordmann JP, Soderstrom M, Rouland JF et al (2000): Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group; *Br J Ophthalmol*, 84, 181-185.

Nouri-Mahdavi K, Javadi MA, Jafarinasab MR (2011): Immunologic corneal graft rejection after administration of topical latanoprost: a report of two patients; *J Ophthalmic Vis Res*, 6, 127-130.

O'Donoghue EP (2000): A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Ireland Latanoprost Study Group; *Br J Ophthalmol*, 84, 579-582.

O'Toole L, Cahill M, O'Brien C (2001): Eyelid hypertrichosis associated with latanoprost is reversible; *Eur J Ophthalmol*, 11, 377-39.

Ocklind A (1998): Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections; *Exp Eye Res*, 67, 179-191.

Oh JY, Park KH (2005): The effect of latanoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma; *Korean J Ophthalmol*, 19, 297-301.

Oh DJ, Martin JL, Williams AJ et al (2006): Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells; *Invest Ophthalmol Vis Sci*, 47, 3887-3895.

Ooi YH, Oh DJ, Rhee DJ (2009): Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells; *Invest Ophthalmol Vis Sci*, 50, 5259-5265.

Orhan M, Kerimoglu H, Irkec M (2003): Corneal neovascularization possibly associated with latanoprost therapy; *Eur J Ophthalmol*, 13, 88-90.

Orme M, Collins S, Dakin H et al (2010): Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension; *Curr Med Res Opin*, 26, 511-528.

Orzalesi N, Rossetti L, Invernizzi T et al (2000): Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension; *Invest Ophthalmol Vis Sci*, 41, 2566-2573.

Orzalesi N, Rossetti L, Bottoli A et al (2003): The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension; *Arch Ophthalmol*, 121, 453-457.

Orzalesi N, Rossetti L, Bottoli A et al (2006): Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension; *Ophthalmology*, 113, 239-246.

Ozdemir H, Karacorlu M, Karacorlu SA (2008): Serous detachment of macula in cystoid macular edema associated with latanoprost; *Eur J Ophthalmol*, 18, 1014-1046.

Ozkan B, Karabas VL, Yuksel N et al (2008): Serous retinal detachment in the macula related to latanoprost use; *Int Ophthalmol*, 28, 363-365.

Ozyol P, Ozyol E, Erdogan BD (2016): The interaction of nepafenac and prostaglandin analogs in primary open-angle glaucoma patients; *J Glaucoma*, 25, e145-e149.

Ozyurt S, Cetinkaya GS (2015): Hypertrichosis of the malar areas and poliosis of the eyelashes caused by latanoprost; *Actas Dermosifiliogr*, 106, 74-75.

Pacella F, Turchetti P, Santamaria V et al (2012): Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension; *Clin Ophthalmol*, 6, 811-815.

Park J, Cho HK, Moon JI (2011): Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost; *Jpn J Ophthalmol*, 55, 22-27.

Park SH, Yoo SH, Ha SJ (2015): Comparison of ocular pulse amplitude-lowering effects of tafluprost and latanoprost by dynamic contour tonometry; *J Ocul Pharmacol Ther*, 31, 617-622.

Parmaksiz S, Yuksel N, Karabas VL et al (2006): A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma; *Eur J Ophthalmol*, 16, 73-80.

Parrish RK, Palmberg P, Sheu WP et al (2003): A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study; *Am J Ophthalmol*, 135, 688-703.

Patel SS, Spencer CM (1996): Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension; *Drugs Aging*, 9, 363-378.

Paul S, Wand M, Emerick GT et al (2014): The role of latanoprost in an inflammatory bowel disease flare; *Gastroenterol Rep*, 2, 232-234.

Pauly A, Brignole-Baudouin F, Guenoun JM et al (2007): Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFN gamma and toxicological profiles; *Graefes Arch Clin Exp Ophthalmol*, 245, 534-546.

Peak AS, Sutton BM (1998): Systemic adverse effects associated with topically applied latanoprost; *Ann Pharmacother*, 32, 504.

Pellinen P, Huhtala A, Tolonen A et al (2012): The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo; *Curr Eye Res*, 37, 145-154.

Perez-Roca F, Rodrigo-Morales E, Garzon I et al (2015): Effects of four formulations of prostaglandin analogs on eye surface cells. A comparative study; *PLoS One*, 10, e0129419.

Perez-Rodriguez E, Gonzalez-Perez R, Poza P et al (2008): Contact dermatitis caused by latanoprost-containing eye drops with good tolerance to bimatoprost eye drops; *Contact Dermatitis*, 58, 370-371.

Perry CM, McGavin JK, Culy CR et al (2003): Latanoprost: an update of its use in glaucoma and ocular hypertension; *Drugs Aging*, 20, 597-630.

Petounis A, Mylopoulos N, Kandarakis A et al (2001): Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece; *J Glaucoma*, 10, 316-324.

Pfeiffer N, Grierson I, Goldsmith H et al (2001): Histological effects in the iris after 3 months of latanoprost therapy: the Mainz I study; *Arch Ophthalmol*, 119, 191-196.

Pfeiffer N, Grierson I, Goldsmith H et al (2003): Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy (the Mainz II study); *Arch Ophthalmol*, 121, 23-31.

Pillunat LE, Larsson LI, European and Canadian Latanoprost Study Group (2003): Intraocular pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open angle glaucoma; *Br J Ophthalmol*, 87, 1492-1496.

Pinheiro R, Panfil C, Schrage N et al (2016): the impact of glaucoma medications on corneal wound healing; *J Glaucoma*, 25, 122-127.

Polo V, Larrosa JM, Gomez ML et al (2001): Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma; *Acta Ophthalmol Scand*, 79, 6-9.

Pozarowska D, Pozarowski P, Darzynkiewicz Z (2010): Cytometric assessment of cytostatic and cytotoxic effects of topical glaucoma medications on human epithelial corneal line cells; *Cytometry B Clin Cytom*, 78, 130-137.

Quaranta L, Gandolfo F, Turano R et al (2006): Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma; *Invest Ophthalmol Vis Sci*, 47, 2917-2923.

Quaranta L, Miglior S, Floriani I et al (2008): Effects of the timolol-dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma; *Invest Ophthalmol Vis Sci*, 49, 4226-4231.

Raber S, Courtney R, Maeda-Chubachi T et al (2011): Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study; *Ophthalmology*, 118, 2022-2027.

Raber S, Mandema JW, Li H et al (2015): A model-based dose-response meta-analysis of ocular hypotensive agents as a drug development tool to evaluate new therapies in glaucoma; *J Ocul Pharmacol Ther*, 31, 189-197.

Rabinowitz MP, Katz LJ, Moster MR et al (2015): Unilateral prostaglandin-associated periorbitopathy: a syndrome involving upper eyelid retraction distinguishable from the aging sunken eyelid; *Ophthalm Plast Reconstr Surg*, 31, 373-378.

Racz P, Ruzsonyi MR, Nagy ZT et al (1993): Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F_{2α} analogue (PhXA41): An in-hospital, placebo-controlled study; *Arch Ophthalmol*, 111, 657-661.

Racz P, Ruzsonyi MR, Nagy ZT et al (1996): Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol; *Arch Ophthalmol*, 114, 268-273.

Raja V, Sandanshiv P, Asghar M et al (2007): Latanoprost-related transient incontinence; *Clin Experiment Ophthalmol*, 35, 389-390.

- Rao S, Narayanan PV (2016): A randomised open label comparative clinical trial on the efficacy of latanoprost and timolol in primary open angle glaucoma; *J Clin Diagn Res*, 10, FC13-FC15.
- Rask-Andersen H, Friberg U, Johansson M et al (2005): Effects of intratympanic injection of latanoprost in Meniere's disease: a randomized, placebo-controlled, double-blind, pilot study; *Otolaryngol Head Neck Surg*, 133, 441-443.
- Razeghinejad MR, Rahat F (2010): Combined phacoemulsification and viscozoniosynechialysis in the management of patients with chronic angle closure glaucoma; *Int Ophthalmol*, 30, 353-359.
- Reis A, Althaus C, Sundmacher R (1998): Latanoprost (Xalatan)-induced macular edema; *Klin Monatsbl Augenheilkd*, 213, 63-64.
- Reynolds A, Murray PI, Colloby PS (1998): Darkening of eyelashes in a patient treated with latanoprost; *Eye*, 12, 741-743.
- Ritch R, Ishikawa H, Rothman R et al (2002): The efficacy of latanoprost is independent of the width of the ciliary body face; *J Glaucoma*, 11, 239-243.
- Rolle T, Cipullo D, Vizzeri GM et al (2000): Evaluation and comparison between the effects on intraocular pressure and retinal blood flow of two antiglaucomatous drugs administered in monotherapy: brimonidine and latanoprost; *Acta Ophthalmol Scand Suppl*, 78, 50-52.
- Rosin LM, Bell NP (2013): Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops; *Clin Ophthalmol*, 7, 2131-2135.
- Roughead EE, Kalisch LM, Pratt NL et al (2012): Managing glaucoma in those with co-morbidity: not as easy as it seems; *Ophthalmic Epidemiol*, 19, 74-82.
- Rouland JF, Traverso CE, Stalmans I et al (2013): Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma; *Br J Ophthalmol*, 97, 196-200.
- Rowe JA, Hattenhauer MG, Herman DC (1997): Adverse side effects associated with latanoprost; *Am J Ophthalmol*, 124, 683-685.
- Rulo AH, Greve EL, Hoyng PF (1994): Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure; *Br J Ophthalmol*, 78, 899-902.
- Rulo AH, Greve EL, Geijssen HC et al (1996): Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma; *Ophthalmology*, 103, 1276-1282.
- Rulo AH, Greve EL, Hoyng PF (1997): Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure; *Ophthalmology*, 104, 1503-1507.
- Russo A, Riva I, Pizzolante T et al (2008): Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review; *Clin Ophthalmol*, 2, 897-905.
- Sacca S, Pascotto A, Siniscalchi C et al (2001): Ocular complications of latanoprost in uveitic glaucoma: three case reports; *J Ocul Pharmacol Ther*, 17, 107-113.

- Saito M, Takano R, Shirato S (2001): Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma; *Am J Ophthalmol*, 132, 485-489.
- Sakai H, Sakima N, Nakamura Y et al (2002): Ciliochoroidal effusion induced by topical latanoprost in a patient with sturge-weber syndrome; *Jpn J Ophthalmol*, 46, 553-555.
- Sakai H, Shinjyo S, Nakamura Y et al (2005): Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients; *J Ocul Pharmacol*, 21, 483-489.
- Sakata R, Shirato S, Miyata K et al (2013): Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost; *Jpn J Ophthalmol*, 57, 179-184.
- Sakata R, Shirato S, Miyata K et al (2014): Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy with a latanoprost ophthalmic solution; *Eye*, 28, 1446-1451.
- Sakurai M, Higashide T, Ohkubo S et al (2014): Association between genetic polymorphisms of the prostaglandin F2 α receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension; *Br J Ophthalmol*, 98, 469-473.
- Sambhara D, Aref AA (2014): Glaucoma management: relative value and place in therapy of available drug treatments; *Ther Adv Chron Dis*, 5, 30-43.
- Sanford M (2014): Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma/ocular hypertension; *Clin Drug Investig*, 34, 521-528.
- Santos HD, Fernandes TA, Souza CA et al (2009): Efficacy of latanoprost versus travoprost assessed by daily intraocular pressure curve; *Arq Bras Oftalmol*, 72, 13-17.
- Santos-Bueso E, Saenz-Frances F, Palmero-Fernandez L et al (2015): Hypertension secondary to treatment with latanoprost; *Arch Soc Esp Oftalmol*, 30, 37-39.
- Sawada A, Yamamoto T, Takatsuka N (2012): Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma; *Graefes Arch Clin Exp Ophthalmol*, 250, 123-129.
- Schachar RA, Raber S, Courtney R et al (2011): A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension; *Curr Eye Res*, 36, 809-817.
- Scherer WJ, Mielke DL, Tidwell PE et al (1998): Effect of latanoprost on intraocular pressure following cataract extraction; *J Cataract Refract Surg*, 24, 964-967.
- Schlote T (2002): Side-effects and risk profile of latanoprost 0.005% (Xalatan); *Ophthalmologe*, 99, 724-729.
- Schumer RA, Camras CB, Mandahl AK (2000): Latanoprost and cystoid macular edema: is there a causal relation?; *Curr Opin Ophthalmol*, 11, 94-100.
- Schumer RA, Camras CB, Mandahl AK (2002): Putative side effects of prostaglandin analogs; *Surv Ophthalmol*, 47(Suppl.1), S219-S230.

Schwartz GF, Kotak S, Mardekian J et al (2011): Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical/pharmacy claims databases; *BMC Ophthalmol*, 11, 14.

Selen F, Tekeli O, Yanik O (2017): Assessment of the anterior chamber flare and macular thickness in patients treated with topical antiglaucomatous drugs; *J Ocul Pharmacol Ther*, Epub ahead of print.

Sen E, Nalcacioglu P, Yazici A et al (2008): Comparison of the effects of latanoprost and bimatoprost on central corneal thickness; *J Glaucoma*, 17, 398-402.

Seong GJ, Lee HK, Hong YJ (1999): Effects of 0.005% latanoprost on optic nerve head and peripapillary retinal blood flow; *Ophthalmologica*, 213, 355-359.

Sharif NA, Crider JY, Husain S et al (2003a): Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca²⁺ mobilization and MAP kinase activation; *J Ocul Pharmacol Ther*, 19, 437-455.

Sharif NA, Kelly CR, Crider JY et al (2003b): Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells; *J Ocul Pharmacol Ther*, 19, 501-515.

Sharif NA, Kelly CR, Crider JY (2003c): Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues; *Invest Ophthalmol Vis Sci*, 44, 715-721.

Sharpe ED, Reynolds AC, Skuta GL et al (2007): The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy; *Curr Eye Res*, 32, 1037-1043.

Shen JW, Shan M, Peng YY et al (2016): Cytotoxic effect of latanoprost on human corneal stromal cells in vitro and its possible mechanisms; *Curr Eye Res*, Epub ahead of print.

Shin JA, Kim NW, Kang SS et al (2016): In vitro effects of prostaglandin analogs on cultured astrocytes obtained from the lamina cribrosa; *Curr Eye Res*, 41, 676-682.

Sihota R, Saxena R, Agarwal HC et al (2004): Crossover comparison of timolol and latanoprost in chronic primary angle-closure glaucoma; *Arch Ophthalmol*, 122, 185-189.

Simmons ST, Samuelson TW (2000): Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group; *Clin Ther*, 22, 388-399.

Simmons ST, Earl ML, Alphagan/Xalatan Study Group (2002): Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering; *Ophthalmology*, 109, 307-314.

Simmons ST, Dirks MS, Noecker RJ (2004): Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials; *Adv Ther*, 21, 247-262.

- Simmons ST, Bernstein P, Hollander DA (2008): A comparison of long-term intraocular pressure fluctuation in patients treated with bimatoprost or latanoprost; *Am J Ophthalmol*, 146, 473-477.
- Sjoquist B, Stjernschantz J (2002): Ocular and systemic pharmacokinetics of latanoprost in humans; *Surv Ophthalmol*, 47(Suppl.1), S6-S12.
- Smedowski A, Paterno JJ, Toropainen E et al (2014): Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells; *J Biochem Pharmacol Res*, 2, 175.
- Smith SL, Pruitt CA, Sine CS et al (1999): Latanoprost 0.005% and anterior segment uveitis; *Acta Ophthalmol*, 77, 668-672.
- Sodhi PK (2003): Iris cyst secondary to latanoprost mimicking iris melanoma; *Am J Ophthalmol*, 136, 780.
- Sodhi PK, Pandey RM, Ratan SK (2003): Efficacy and safety of brimonidine, dorzolamide and latanoprost as adjunctive therapy in primary open angle glaucoma; *Int J Clin Pract*, 57, 875-878.
- Sponsel WE, Paris G, Trigo Y et al (2002a): Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy; *Am J Ophthalmol*, 133, 11-18.
- Sponsel W, Paris G, Trigo Y et al (2002b): Comparative effects of latanoprost (Xalatan) and unoprostone (Rescula) in patients with open-angle glaucoma and suspected glaucoma; *Am J Ophthalmol*, 134, 552-557.
- Stalmans I, Oddone F, Cordeiro MF et al (2016): Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial; *Graefes Arch Clin Exp Ophthalmol*, 254, 1151-1158.
- Stanimirovic A, Kovacevic M, Korobko I et al (2016): Combined therapy for resistant vitiligo lesions: NB-UVB, microneedling, and topical latanoprost, showed no enhanced efficacy compared to topical latanoprost and NB-UVB; *Dermatol Ther*, 29, 312-316.
- Steigerwalt RD, Vingolo EM, Plateroti P et al (2012): The effect of latanoprost and influence of changes in body position on patients with glaucoma and ocular hypertension; *Eur Rev Med Pharmacol Sci*, 16, 1723-1728.
- Stewart O, Walsh L, Pande M (1999): Bilateral optic disc oedema associated with latanoprost; *Br J Ophthalmol*, 83, 1092-1093.
- Stewart WC, Day DG, Stewart JA et al (2000): Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension; *J Ocul Pharmacol Ther*, 16, 557-564.
- Stewart WC, Day DG, Stewart JA et al (2001): The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension; *Am J Ophthalmol*, 131, 631-635.
- Stewart WC, Kolker AE, Stewart JA et al (2003a): Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost; *Am J Ophthalmol*, 135, 314-320.

- Stewart WC, Stewart JA, Jenkins JN et al (2003b): Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects; *J Glaucoma*, 12, 475-479.
- Stewart WC, Konstas AG, Nelson LA et al (2008): Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines; *Ophthalmology*, 115, 1117.e1-1122.e1.
- Stjernschantz JW (2001): From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture; *Invest Ophthalmol Vis Sci*, 42, 1134-1145.
- Stjernschantz JW, Albert DM, Hu DN et al (2002): Mechanism and clinical significance of prostaglandin-induced iris pigmentation; *Surv Ophthalmol*, 47(Suppl.1), S162-S175.
- Strober BE, Potash S, Grossman ME (2001): Eyelash hypertrichosis in a patient treated with topical latanoprost; *Cutis*, 67, 109-110.
- Sudesh S, Cohen EJ, Rapuano CJ et al (1999): Corneal toxicity associated with latanoprost; *Arch Ophthalmol*, 117, 539-540.
- Sugiyama T, Kojima S, Ishida O et al (2009): Changes in optic nerve head blood flow induced by the combined therapy of latanoprost and beta blockers; *Acta Ophthalmol*, 87, 797-800.
- Susanna R, Giampani J, Borges AS et al (2001): A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension; *Ophthalmology*, 108, 259-263.
- Suzuki M, Mishima HK, Masuda K et al (2000): Efficacy and safety of latanoprost eye drops for glaucoma treatment: a 1-year study in Japan; *Jpn J Ophthalmol*, 44, 33-38.
- Syed MI, Ilan O, Nassar J et al (2015): Intratympanic therapy in Meniere's syndrome or disease: up to date evidence for clinical practice; *Clin Otolaryngol*, 40, 682-690.
- Takahashi H, Kashiwagi K, Kogure S et al (2003): Bullous keratopathy after argon laser iridotomy presumably associated with latanoprost; *Jpn J Ophthalmol*, 47, 618-620.
- Tamada Y, Taniguchi T, Murase H et al (2001): Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma; *J Ocul Pharmacol Ther*, 17, 19-25.
- Tamaki Y, Nagahara M, Araie M et al (2001): Topical latanoprost and optic nerve head and retinal circulation in humans; *J Ocul Pharmacol Ther*, 17, 403-411.
- Tamer C, Oksuz H (2007): Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost; *Ophthalmic Res*, 39, 24-31.
- Tan J, Berke S (2013): Latanoprost-induced prostaglandin-associated periorbitopathy; *Optom Vis Sci*, 90, e245-e247.
- Tanihara H, Inoue T, Yamamoto T et al (2015): Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (k-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials; *JAMA Ophthalmol*, 133, 755-761.

- Terai N, Schlotzer-Schrehardt U, Lampel J et al (2009): Effect of latanoprost and timolol on the histopathology of the human conjunctiva; *Br J Ophthalmol*, 93, 219-224.
- Teus MA, Arranz-Márquez E, Lucea-Suescun P (2002): Incidence of iris colour change in latanoprost treated eyes; *Br J Ophthalmol*, 86, 1085-1088.
- Thelen U, Schnober D, Scholzel S et al (2013): Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany; *Int J Ophthalmol*, 6, 155-159.
- Thygesen J, Aaen K, Theodorsen F et al (2000): Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension; *Acta Ophthalmol Scand*, 78, 37-44.
- Tilma KK, Bek T (2012): Topical treatment for 1 week with latanoprost but not diclofenac reduces the diameter of dilated retinal arterioles in patients with type 1 diabetes mellitus and mild retinopathy; *Acta Ophthalmol*, 90, 750-755.
- Tokunaga T, Kashiwagi K, Saito J et al (2002): A case of cystoid macular edema associated with latanoprost ophthalmic solution; *Jpn J Ophthalmol*, 46, 656-659.
- Tomita G, Araie M, Kitazawa Y et al (2004): A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients; *Eye*, 18, 984-989.
- Toris CB, Camras CB, Yablonski ME (1993): Effects of PhXA41, a new prostaglandin F_{2α} analog, on aqueous humor dynamics in human eyes; *Ophthalmology*, 100, 1297-1304.
- Toris CB, Alm A, Camras CB (2002): Latanoprost and cholinergic agonists in combination; *Surv Ophthalmol*, 47(Suppl.1), S141-S147.
- Traverso CE, Ropo A, Papadia M et al (2010): A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost; *J Ocul Pharmacol Ther*, 26, 97-104.
- Tressler CS, Wiseman RL, Dombi TM et al (2011): Lack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literature; *Br J Ophthalmol*, 95, 1490-1495.
- Tsai JC, Sivak-Callcott JA, Haik BG et al (2001): Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report; *J Glaucoma*, 10, 411-413.
- Tsikripis P, Papaconstantinou D, Koutsandrea C et al (2013): The effect of prostaglandin analogs on the biomechanical properties and central thickness of the cornea of patients with open-angle glaucoma: a 3-year study on 108 eyes; *Drug Des Devel Ther*, 7, 1149-1156.
- Tsukamoto H, Jian K, Takamatsu M et al (2003): Additive effect of bunazosin on intraocular pressure when topically added to treatment with latanoprost in patients with glaucoma; *Jpn J Ophthalmol*, 47, 526-528.

Tsukamoto H, Noma H, Matsuyama S et al (2005): The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma; *J Ocul Pharmacol*, 21, 170-173.

Tsukamoto H, Noma H, Mishima HK (2006): Correlation between the additive effect of bunazosin and the response to latanoprost on intraocular pressure in patients with glaucoma treated with bunazosin as adjunctive therapy to latanoprost; *Jpn J Ophthalmol*, 50, 65-67.

Tsuru T, Kitazawa Y, Usui M et al (2008): The additive effects on intraocular pressure of combining niprotilol 0.25% and latanoprost 0.005% ophthalmic solutions: a prospective, randomized, multicenter study; *Jpn J Ophthalmol*, 52, 368-373.

Ulas F, Balbaba M, Celebi S (2013): Effect of prophylactic intraocular pressure-lowering medication on pain during cataract surgery; *J Ocul Pharmacol Ther*, 29, 658-662.

Ung T, Currie ZI (2012): Periocular changes following long-term administration of latanoprost 0.005%; *Ophthal Plast Reconstr Surg*, 28, e42-e44.

Urban B, Bakunowicz-Lazarczyk A, Mrugacz M et al (2004): The effectiveness of latanoprost for the treatment of pediatric glaucoma; *Klin Oczna*, 106(Suppl.1-2), 243-244.

Ussa F, Fernandez I, Brion M et al (2015): Association between SNPs of metalloproteinases and prostaglandin F2 α receptor genes and latanoprost response in open-angle glaucoma; *Ophthalmology*, 122, 1040.e4-1048.e4.

Uusitalo H, Kaarniranta K, Ropo A (2008): Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers; *Acta Ophthalmol Suppl*, 242, 7-13.

Uusitalo H, Pillunat LE, Ropo A (2010): Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study; *Acta Ophthalmol*, 88, 12-19.

Uva MG, Longo A, Reibaldi M (2009): Pneumatic trabeculoplasty vs latanoprost as adjunctive therapy to timolol in primary open-angle glaucoma or ocular hypertension; *Graefes Arch Clin Exp Ophthalmol*, 247, 1103-1109.

Uva MG, Avitabile T, Reibaldi M et al (2014): Long-term efficacy of latanoprost in primary congenital glaucoma; *Eye*, 28, 53-57.

van der Valk R, Webers CA, Schouten JS et al (2005): Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials; *Ophthalmology*, 112, 1177-1185.

van der Valk R, Webers CA, Lumley T et al (2009): A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure; *J Clin Epidemiol*, 62, 1279-1283.

Varma R, Hwang LJ, Grunden JW et al (2009): Assessing the efficacy of latanoprost vs timolol using an alternate efficacy parameter: the intervisit intraocular pressure range; *Am J Ophthalmol*, 148, 221-226.

- Varma R, Hwang LJ, Grunden JW et al (2010): Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy; *Br J Ophthalmol*, 94, 80-84.
- Vetrugno M, Cantatore F, Gigante G et al (1998): Latanoprost 0.005% in POAG: effects on IOP and ocular blood flow; *Acta Ophthalmol Scand Suppl*, 227, 40-41.
- Vetrugno M, Maino A, Quaranta GM et al (2000): A randomized, comparative open-label study on the efficacy of latanoprost and timolol in steroid induced ocular hypertension after photorefractive keratectomy; *Eur J Ophthalmol*, 10, 205-211.
- Villegas VM, Diaz L, Izquierdo NJ (2008): Herpetic keratitis in a patient who used two different prostaglandin analogue ophthalmic solutions: a case report; *P R Health Sci J*, 27, 348-349.
- Villumsen J, Alm A (1989): Prostaglandin F₂ α -isopropylester eye drops: effects in normal human eyes; *Br J Ophthalmol*, 73, 419-426.
- Waldock A, Snape J, Graham CM (2000): Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients; *Br J Ophthalmol*, 84, 710-713.
- Walimbe T, Chelerkar V, Bhagat P et al (2016): Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma; *Clin Ophthalmol*, 10, 821-827.
- Walters TR, DuBiner HB, Carpenter SP et al (2004): 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial; *Surv Ophthalmol*, 49 (Suppl 1), S26-S35.
- Wand M (1997): Latanoprost and hyperpigmentation of eyelashes; *Arch Ophthalmol*, 115, 1206-1208.
- Wand M, Gilbert CM, Liesegang TJ (1999): Latanoprost and herpes simplex keratitis; *Am J Ophthalmol*, 127, 602-604.
- Wand M, Ritch R, Isbey EK et al (2001a): Latanoprost and periocular skin color changes; *Arch Ophthalmol*, 119, 614-615.
- Wand M, Gaudio AR, Shields MB (2001b): Latanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyes; *J Cataract Refract Surg*, 27, 1397-1401.
- Wang NL, Lu QJ, Li JH et al (2008): Prostaglandin induces the expression of matrix metalloproteinase-1 in ciliary melanocytes; *Chin Med J (Engl)*, 121, 1173-1176.
- Wardrop DR, Wishart PK (1998): Latanoprost and cystoid macular oedema in a pseudophake; *Br J Ophthalmol*, 82, 843-844.
- Warwar RE, Bullock JD, Ballal D (1998): Cystoid macular edema and anterior uveitis associated with latanoprost use; Experience and incidence in a retrospective review of 94 patients; *Ophthalmology*, 105, 263-268.
- Watanabe K, Hayasaka S, Hayasaka Y et al (2003): Cystoid macular edema associated with latanoprost use in a pseudophakic eye with a history of surgical complications; *Jpn J Ophthalmol*, 47, 110-112.

- Watson P, Stjernschantz J, The Latanoprost Study Group (1996): A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group; *Ophthalmology*, *103*, 126-137.
- Watson PG, the Latanoprost Study Group (1998): Latanoprost: Two years' experience of its use in the United Kingdom; *Ophthalmology*, *105*, 82-87.
- Webers CA, van der Valk R, Schouten JS et al (2007): Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta analysis of randomized clinical trials; *Ophthalmology*, *114*, 40-46.
- Webers CA, Beckers HJ, Zeegers MP et al (2010): The intraocular pressure-lowering effect of prostaglandin analogs combined with topical β -blocker therapy: a systematic review and meta-analysis; *Ophthalmology*, *117*, 2067.e1-6-2074.e1-6.
- Weinreb RN, Lindsey JD (2002): Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost; *Invest Ophthalmol Vis Sci*, *43*, 716-722.
- Weinreb RN, Kashiwagi K, Kashiwagi F et al (1997): Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells; *Invest Ophthalmol Vis Sci*, *38*, 2772-2780.
- Weinreb RN, Lindsey JD, Marchenko G et al (2004): Prostaglandin FP agonists alter metalloproteinase gene expression in sclera; *Invest Ophthalmol Vis Sci*, *45*, 4368-4377.
- Weinreb RN, Ong T, Scassellati Sforzolini B et al (2015): A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study; *Br J Ophthalmol*, *99*, 738-745.
- Weston BC (2001): Migraine headache associated with latanoprost; *Arch Ophthalmol*, *119*, 300-301.
- Whitson JT, Trattler WB, Matossian C et al (2010): Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension; *J Ocul Pharmacol Ther*, *26*, 287-292.
- Widengard I, Maepea O, Alm A (1998): Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability; *Br J Ophthalmol*, *82*, 404-406.
- Wierzbowska J, Lagocka A, Siemiatkowska A et al (2009): The impact of common classes of topical antiglaucoma medications on central corneal thickness--own observations; *Klin Oczna*, *111*, 323-326.
- Wstrand PJ, Stjernschantz J, Olsson K (1997): The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color; *Surv Ophthalmol*, *41*(Suppl.2), S129-S138.
- Woo TL, Franzco IF (2001): Intermittent blurred vision and trichomegaly due to latanoprost; *Clin Experiment Ophthalmol*, *29*, 272-273.
- Wu N, Chen Y, Yu X et al (2016): Changes in corneal biomechanical properties after long-term topical prostaglandin therapy; *PLoS One*, *11*, e0155527.

Xalatan SPC (2017): Xalatan 0.005% eye drops solution; Accessed online at: <http://www.medicines.org.uk/emc/medicine/9043/SPC/Xalatan+0.005++eye+drops+solution/> [Accessed on 14 February 2017].

Yamada H, Yoneda M, Goshō M et al (2016): Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases; *BMC Ophthalmol*, 16, 26.

Yanagi M, Kiuchi Y, Yuasa Y et al (2016): Association between glaucoma eye drops and hyperemia; *Jpn J Ophthalmol*, 60, 72-77.

Yang CB, Freedman SF, Myers JS et al (1998): Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome; *Am J Ophthalmol*, 126, 600-602.

Yeh PC, Ramanathan S (2002): Latanoprost and clinically significant cystoid macular edema after uneventful phacoemulsification with intraocular lens implantation; *J Cataract Refract Surg*, 28, 1814-1818.

Yildirim N, Sahin A, Gultekin S (2008): The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma; *J Glaucoma*, 17, 36-39.

Yoo R, Choi YA, Cho BJ (2017): Change in central corneal thickness after the discontinuation of latanoprost in normal tension glaucoma-change in central corneal thickness after stop of latanoprost; *J Ocul Pharmacol Ther*, 33, 57-61.

You JY, Cho BJ (2013): Effect of latanoprost on central corneal thickness in unilateral normal-tension glaucoma; *J Ocul Pharmacol Ther*, 29, 335-338.

Yu M, Chen X, Jia et al (2009): Travoprost and latanoprost, but not bimatoprost, induced nausea, vomiting and diarrhea; *BMJ Case Rep*, 2009, bcr08.2008.0618.

Zavorkova M, Susicky P (2007): Five years retrospective study of latanoprost glaucoma treatment; *Cesk Slov Oftalmol*, 63, 292-298.

Zeitz O, Matthiessen ET, Reuss J et al (2005): Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide; *BMC Ophthalmology*, 5, 1-11.

Zhang WY, Po AL, Dua HS et al (2001): Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension; *Br J Ophthalmol*, 85, 983-990.

Zhang P, Jiang B, Xie L et al (2016): PTGFR and SLCO2A1 gene polymorphisms determine intraocular pressure response to latanoprost in han chinese patients with glaucoma; *Curr Eye Res*, 41, 1561-1565.

Zhao X, Pearson KE, Stephan DA et al (2003): Effects of prostaglandin analogues on human ciliary muscle and trabecular meshwork cells; *Invest Ophthalmol Vis Sci*, 44, 1945-1952.

Zhao J, Ge J, Sun X et al (2013): Intraocular pressure-reducing effects of latanoprost versus timolol in chinese patients with chronic angle-closure glaucoma; *J Glaucoma*, 22, 591-596.

Zhong Y, Shen X, Yu J et al (2011): The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness; *Cornea*, 30, 861-864.

Ziai N, Dolan JW, Kacere RD et al (1993): The effects on aqueous dynamics of PhXA41, a new prostaglandin F₂ α analogue, after topical application in normal and ocular hypertensive human eyes; *Arch Ophthalmol*, 111, 1351-1358.